Pulmonary Fibrosis: Scarring of the Lungs

Pulmonary fibrosis is a progressive lung disease characterized by the accumulation of scar tissue (fibrosis) within the lungs, which stiffens the organ and impairs gas exchange. This page covers the definition and biological scope of the condition, the cellular mechanisms driving fibrosis, the clinical scenarios in which it arises, and the diagnostic and classification boundaries that distinguish subtypes from one another. Understanding these distinctions matters because treatment eligibility, prognosis, and regulatory approval for therapies differ significantly across the disease spectrum.

Definition and scope

Pulmonary fibrosis describes a pathological process in which normal lung parenchyma is replaced by dense connective tissue, reducing the lungs' ability to expand and transfer oxygen into the bloodstream. The broadest diagnostic umbrella is interstitial lung disease (ILD), a category encompassing more than 200 distinct conditions affecting the lung interstitium — the tissue and space surrounding the air sacs.

The most studied subtype is idiopathic pulmonary fibrosis (IPF), classified by the American Thoracic Society (ATS) and the European Respiratory Society (ERS) in their joint 2022 clinical practice guidelines (ATS/ERS/JRS/ALAT IPF Guideline 2022) as a chronic, progressive fibrosing interstitial pneumonia of unknown cause occurring primarily in adults older than 60. IPF carries a median survival of 3 to 5 years from diagnosis, according to the National Heart, Lung, and Blood Institute (NHLBI).

Pulmonary fibrosis as a broader phenomenon appears across a range of conditions catalogued in the ICD-10-CM under codes J84.x (Other interstitial pulmonary diseases). Globally, IPF alone affects an estimated 3 million people, based on epidemiological estimates cited by the Pulmonary Fibrosis Foundation (PFF).

The regulatory context for pulmonary conditions in the United States is shaped in part by FDA orphan drug designations, which have been granted to IPF therapies because the condition affects fewer than 200,000 individuals in the US under the Orphan Drug Act (21 U.S.C. § 360bb).

How it works

The fibrotic process begins at the level of the alveolar epithelium — the thin cellular lining of the 300 to 500 million air sacs in a healthy adult lung (NHLBI Lung Biology). Repeated micro-injury to these epithelial cells, whether from inhaled particles, gastric reflux microaspiration, viral infection, or genetic susceptibility, triggers an abnormal wound-healing response.

The pathological sequence proceeds through discrete phases:

  1. Epithelial injury — Type II pneumocytes sustain repetitive damage and activate stress-response pathways.
  2. Aberrant repair signaling — Transforming growth factor beta-1 (TGF-β1) is released, driving fibroblast recruitment and differentiation into myofibroblasts.
  3. Extracellular matrix deposition — Myofibroblasts lay down excessive collagen, particularly type I and III collagen, stiffening the alveolar walls.
  4. Architectural distortion — Honeycombing (cystic airspace clusters) and traction bronchiectasis develop as normal tissue is replaced.
  5. Physiologic impairment — Reduced lung compliance forces higher respiratory effort; diffusion capacity (DLCO) falls, restricting oxygen transfer.

High-resolution computed tomography (HRCT) imaging is the primary non-invasive tool for detecting the characteristic usual interstitial pneumonia (UIP) pattern — the radiological hallmark of IPF — consisting of basal-predominant, subpleural honeycombing with or without peripheral traction bronchiectasis. The ATS/ERS 2022 guidelines define four HRCT confidence categories for UIP: typical UIP, probable UIP, indeterminate for UIP, and alternative diagnosis.

Two FDA-approved antifibrotic agents — pirfenidone and nintedanib — slow the rate of forced vital capacity (FVC) decline by approximately 50% compared to placebo in clinical trials (FDA Drug Approvals for IPF). Neither reverses established fibrosis; they attenuate progression.

Common scenarios

Pulmonary fibrosis arises in recognizable clinical contexts that guide differential diagnosis:

Idiopathic IPF presents in a person over 60 with no identifiable environmental or connective tissue cause, a UIP pattern on HRCT, and progressive dyspnea on exertion. Bibasilar Velcro-like crackles on auscultation and digital clubbing are physical examination findings associated with IPF in peer-reviewed literature (ATS Clinical Practice Guidelines).

Connective tissue disease-associated ILD (CTD-ILD) occurs when systemic autoimmune conditions — including rheumatoid arthritis, systemic sclerosis (scleroderma), and Sjögren's syndrome — drive lung inflammation and fibrosis. Scleroderma-associated ILD develops in up to 70% of patients with diffuse cutaneous systemic sclerosis, according to the American College of Rheumatology (ACR).

Hypersensitivity pneumonitis (HP) results from repeated inhalation of organic antigens — bird proteins, mold spores, or agricultural dusts — and can progress to fibrotic HP if exposure continues. This condition intersects with occupational lung disease scenarios, particularly in farmers, bird handlers, and woodworkers.

Drug-induced pulmonary fibrosis is documented with amiodarone, methotrexate, bleomycin, and nitrofurantoin. The National Institutes of Health maintains the LiverTox database for drug-induced hepatic injury; an analogous resource for pulmonary toxicity, Pneumotox (pneumotox.com), catalogs more than 1,000 drugs associated with pulmonary adverse effects.

Post-COVID fibrosis has been characterized in imaging studies following severe SARS-CoV-2 pneumonia, though its long-term trajectory remains under active investigation across registries coordinated by the NHLBI.

Decision boundaries

Distinguishing subtypes of pulmonary fibrosis determines whether surgical lung biopsy is required, which antifibrotic regimen is appropriate, and whether a patient qualifies for lung transplant evaluation — a threshold governed by the Organ Procurement and Transplantation Network (OPTN) criteria administered by the United Network for Organ Sharing (UNOS) (OPTN Lung Allocation Policy).

IPF versus fibrotic HP: IPF shows typical UIP on HRCT with no identifiable antigen exposure. Fibrotic HP may share a UIP-like pattern but involves upper- or mid-lung fibrosis and a positive exposure history. Bronchoalveolar lavage (BAL) lymphocytosis greater than 20–30% favors HP over IPF.

IPF versus NSIP (nonspecific interstitial pneumonia): NSIP, more common in women and those with connective tissue disease, shows a ground-glass opacity pattern with subpleural sparing on HRCT — a distribution absent in classic UIP. NSIP has a better prognosis than IPF, with 5-year survival rates exceeding 70% in the cellular subtype (ATS/ERS ILD Guidelines).

Staging and severity in IPF is typically measured by:

Transplant listing criteria under OPTN include a Lung Allocation Score (LAS) system that weighs predicted 1-year mortality on the waitlist against post-transplant survival probability. IPF patients receive a substantially higher LAS baseline than patients with obstructive lung disease, reflecting the steeper natural decline trajectory.

The full scope of pulmonary medicine conditions is catalogued on the pulmonaryauthority.com index, providing context for where fibrotic lung disease fits within pulmonology's broader diagnostic landscape.

Pulmonary function tests, including spirometry, DLCO measurement, and plethysmography, are the primary quantitative tools used to establish severity thresholds at each decision boundary described above.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)